| VRTX34 Stock | | | BRL 699.93 9.67 1.36% |
CEO
Reshma Kewalramani is President, Chief Executive Officer, Director of Vertex Pharmaceuticals Incorporated since 2020.
| Age | 45 |
| Tenure | 4 years |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Vertex Pharmaceuticals Incorporated has accumulated 509.8
M in total debt with debt to equity ratio
(D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.52, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vertex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CEO Age |
| Eric Yuan | Zoom Video Communications | 53 |
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 3400 people. Vertex Pharmaceuticals Incorporated (VRTX34) is traded on Sao Paulo Exchange in Brazil and employs 4,800 people.
Management Performance
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | |
| Reshma Kewalramani, President, Chief Executive Officer, Director | |
| Michael Parini, Executive Vice President Chief Legal and Administrative Officer | |
| Alan Garber, Independent Director | |
| Mike Tirozzi, SVP Officer | |
| Damian Esq, Chief VP | |
| Jeffrey MD, Ex Chairman | |
| MD FASN, Pres CEO | |
| Stuart BSc, Ex COO | |
| John Gray, Senior Vice President Genetic Therapies | |
| Margaret McGlynn, Independent Director | |
| Diana McKenzie, Independent Director | |
| Sangeeta Bhatia, Independent Director | |
| Terrence Kearney, Independent Director | |
| Nia Tatsis, Senior Vice President Chief Regulatory Officer | |
| Kristen Ambrose, Tax, Accounting | |
| Paul Silva, Senior Vice President Controller | |
| David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | |
| Amit Sachdev, Executive Vice President Chief Regulatory Officer and Chief of Staff to the CEO | |
| Charles Wagner, Chief Financial Officer, Executive Vice President | |
| Gerald Bruce, Executive Vice President Commercial Operations | |
| Ourania Tatsis, Ex Officer | |
| Bruce Sachs, Co-Lead Independent Director | |
| Susie Lisa, VP Relations | |
| Lloyd Carney, Independent Director | |
| Yuchun Lee, Independent Director | |
| Stuart Arbuckle, Executive Vice President Chief Commercial Officer | |
| Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | |
| Jeffrey Leiden, Executive Chairman of the Board | |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.